PLx Pharma Winddown Corp.
PLXPQ
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -94.17% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -94.17% | -- | -- | 398,075.00% | -- |
| Cost of Revenue | -62.69% | -- | -- | -- | -- |
| Gross Profit | -139.73% | -- | -- | 175,000.00% | -- |
| SG&A Expenses | -16.99% | 148.18% | 600.15% | 745.20% | 455.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.88% | 131.77% | 464.09% | 507.98% | 416.83% |
| Operating Income | -9.91% | -124.32% | -406.15% | -464.80% | -209.32% |
| Income Before Tax | 60.74% | 28.16% | 6.54% | 144.63% | -592.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 60.74% | 28.16% | 6.54% | 144.63% | -592.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.74% | 28.16% | 6.54% | 144.63% | -592.21% |
| EBIT | -9.91% | -124.32% | -406.15% | -464.80% | -209.32% |
| EBITDA | -9.94% | -124.86% | -409.14% | -468.14% | -211.63% |
| EPS Basic | 63.06% | 45.89% | 45.99% | 114.81% | -103.08% |
| Normalized Basic EPS | 63.05% | 38.68% | 44.46% | 115.75% | -135.52% |
| EPS Diluted | 63.06% | 45.89% | 45.99% | 114.75% | -101.05% |
| Normalized Diluted EPS | 63.05% | 38.68% | 44.46% | 115.75% | -135.52% |
| Average Basic Shares Outstanding | 6.29% | 17.16% | 68.32% | 183.39% | 193.92% |
| Average Diluted Shares Outstanding | 6.29% | 17.16% | 68.32% | 183.39% | 193.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |